Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Watzka, SB; Posch, F; Hochmair, M; Setinek, U; Köstler, WJ; Müller, MR.
Resistance to EGFR targeting therapies in lung cancer.
Minerva Chir. 2011; 66(5): 483-494.
Web of Science
PubMed
- Co-Autor*innen der Med Uni Graz
- Posch Florian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- The treatment of advanced non-small cell lung cancer (NSCLC) by therapies targeting the epidermal growth factor receptor (EGFR) pathway represents one of the most important advances in thoracic oncology. Reversible EGFR tyrosine kinase inhibitors (TKIs), like gefitinib and erlotinib, are able to achieve dramatic responses in a subset of patients. However, most patients treated with TKIs eventually develop resistance against these drugs. Here we review the physiology and pathology of EGFR activation in NSCLC, the clinical experience with TKIs, the mechanisms of resistance against TKIs, and discuss various approaches to treat resistance against TKIs.
- Find related publications in this database (using NLM MeSH Indexing)
- Carcinoma, Non-Small-Cell Lung - drug therapy
- Drug Resistance, Neoplasm -
- Humans -
- Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - physiology
- Find related publications in this database (Keywords)
- Non-small cell lung cancer
- Receptor, epidermal growth factor
- Lung neoplasms